Semiconductor supply chain risk for European buyers rises with limited EUV, HBM, and advanced packaging access. Mitigation strategies are essential.
Qualität von deutschen SaaS messen: NRR, Payback und Net Retention zeigen Wachstum, Kundenbindung und Effizienz. Benchmarks und Tipps für nachhaltigen Erfolg.
Orphan-drug pricing in EU5: Germany-first launches shape access and pricing for neuromuscular disease therapies, impacting patient equity and market strategy.
EU AI-Gesetz Bereitschaft: Was SaaS-Anbieter und -Einsetzer bis Q4 2025 beachten und umsetzen müssen, um Compliance und Sicherheit zu gewährleisten.
Biosimilar market entry in Germany for adalimumab is shaped by tendering, hospital procurement, and regional policies driving uptake and cost-savings.
EMA vs FDA timelines for CAR-T in rare oncology differ, with FDA often granting faster approvals while EMA requires more data, affecting patient access.
AMNOG in Practice: Germany evaluates GLP-1 obesity drugs by assessing clinical effectiveness, real-world data, and patient access for obesity treatment.
Tech equity forecasts for 2025 highlight AI, 5G, and IoT adoption trends, revealing top sectors and regions for investors seeking long-term growth.
Energy Equity Beta analysis shows renewables have higher volatility than oil, with electricity prices, capacity, and oil dynamics shaping sector risk.
Equity Report Glossary clarifies essential terms for investors in 2025, helping you analyze stocks, manage risk, and strengthen your portfolio.